Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...

As respiratory virus season begins, pediatric experts are preparing for an expected rise in cases of Respiratory Syncytial ...

The respiratory syncytial virus vaccine is effective in reducing emergency visits, hospitalizations, and severe illness in ...

Revaccination with mRNA-1345 against RSV at 12 months was noninferior to primary vaccination among adults aged 50 years and older.

As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid ...